Novartis: A Mispriced Hedge In A Crowded Equity Market
Source: SeekingAlpha
2025-12-28 04:09:46 ET
Thesis
Capital is flocking to a few high-growth AI plays and ignoring other opportunities because of the AI trend in the markets. The fear of a patent cliff (loss of revenue from a drug going off-patent) for Novartis is already being offset and should normalize over time by volume growth from newer therapies....
Read the full article on Seeking Alpha
For further details see:
Novartis: A Mispriced Hedge In A Crowded Equity Market
Novartis AG
NASDAQ: NVS
NVS Trading
-1.36% G/L:
$143.37 Last:
954,184 Volume:
$144.01 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
